Your browser doesn't support javascript.
loading
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo, Adam; Herter, Sylvia; Grosmaire, Laura; Jones, Randy; Frey, Christian R; Limani, Florian; Bacac, Marina; Umana, Pablo; Oldham, Robert J; Marshall, Michael J E; Cox, Kerry L; Turaj, Anna H; Cragg, Mark S; Klein, Christian; Carter, Matthew J; Tannheimer, Stacey.
Afiliação
  • Palazzo A; Gilead Sciences, Inc., Foster City, CA 98102; adam.palazzo@gilead.com.
  • Herter S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, CH-8952 Zurich, Switzerland; and.
  • Grosmaire L; Gilead Sciences, Inc., Foster City, CA 98102.
  • Jones R; Gilead Sciences, Inc., Foster City, CA 98102.
  • Frey CR; Gilead Sciences, Inc., Foster City, CA 98102.
  • Limani F; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, CH-8952 Zurich, Switzerland; and.
  • Bacac M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, CH-8952 Zurich, Switzerland; and.
  • Umana P; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, CH-8952 Zurich, Switzerland; and.
  • Oldham RJ; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Marshall MJE; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Cox KL; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Turaj AH; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Cragg MS; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Klein C; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, CH-8952 Zurich, Switzerland; and.
  • Carter MJ; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, United Kingdom.
  • Tannheimer S; Gilead Sciences, Inc., Foster City, CA 98102.
J Immunol ; 200(7): 2304-2312, 2018 04 01.
Article em En | MEDLINE | ID: mdl-29453281
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article